The Phase 2 double-blind placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integrity in older persons with severe acute exacerbation of COPD. Rejuvenate Biomed anticipates commencing patient enrollment first half 2025

Rejuvenate Biomed to accelerate its drug development pipeline of assets for age-related diseases using jointly developed tools

Cutting-edge therapy shows meaningful improvements in muscle strength, function and fatigue resistance, offering hope for millions suffering from sarcopenia.